The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
60
vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
Blood draw
Pfizer Investigational Site
Herston, Australia
Pfizer Investigational Site
North Adelaide, Australia
Pfizer Investigational Site
Subiaco, Australia
Safety of 3 doses of MnB rLP2086 vaccine candidate assessed by frequency of solicited local and systemic reactions collected for 7 days after each study vaccination; evaluation of occurrence of AE and SAE during the duration of study
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.